Trade SMMT stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Summit Therapeutics Inc. (SMMT) is trading at US$17.54, up 1.50% today as of Sep 9, 16:00 EDT. The company has a market capitalisation of US$10.5B. Over the past 52 weeks, SMMT has traded between US$12.07 and US$29.23. On Syfe you can trade SMMT with $0 commission and add it to your watchlist.
| Previous close | US$17.28 |
|---|---|
| Market cap | US$10.5B |
| 52-week range | US$12.07 – US$29.23 |
| Volume | 4.73M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Summit Therapeutics Inc.
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Year: 2015
Summit Therapeutics Inc. (SMMT) stock is trading at US$17.54, +1.50% from the previous close of US$17.28.
The market cap for Summit Therapeutics Inc. (SMMT) stock is approximately US$10.5B.
The 52-week high for Summit Therapeutics Inc. (SMMT) stock is US$29.23.
The 52-week low for Summit Therapeutics Inc. (SMMT) stock is US$12.07.
Summit Therapeutics Inc. (SMMT) does not currently pay a dividend.
Stay on top of SMMT
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
